Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Specimen Handling 186pembrolizumab 151Magnetic Resonance Spectroscopy 151Carboplatin 114Biopsy 104Cyclophosphamide 96Cisplatin 88Paclitaxel 79Gemcitabine 71Bevacizumab 68fludarabine 60Nivolumab 58Fluorouracil 51Radiotherapy 49Dexamethasone 47Capecitabine 47Pemetrexed 46Oxaliplatin 44Docetaxel 44Rituximab 43Leucovorin 41Doxorubicin 40venetoclax 39durvalumab 39atezolizumab 39Temozolomide 32Standard of Care 32Radiation 32Cetuximab 32130-nm albumin-bound paclitaxel 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Vaccines, DNA × 30 days × Clear all
NCT06631092 2026-05-26

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

NEC Bio B.V

Phase 1/2 Recruiting
28 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡